Literature DB >> 16689762

The prothrombin 20209 C-->T mutation in Jewish-Moroccan Caucasians: molecular analysis of gain-of-function of 3' end processing.

S Danckwardt1, K Hartmann, B Katz, M W Hentze, Y Levy, R Eichele, V Deutsch, A E Kulozik, O Ben-Tal.   

Abstract

BACKGROUND: Mutations of the 3' end mRNA-processing signal of the prothrombin (F2) gene have been reported to cause elevated F2 plasma concentrations, thrombosis, and complications of pregnancy. Whereas the common F2 20210*A mutation is almost exclusively found in Caucasians, the F2 20209*T mutation has been reported in Afro-Americans and Afro-Caribbeans only. PATIENTS AND METHODS: Using LightCycler technology, three unrelated Jewish-Moroccan patients tested for obstetric complications were found to be carriers of the F2 20209*T allele. A detailed molecular analysis was performed to identify the functional impact of this mutation.
RESULTS: We report three unrelated women of Jewish-Moroccan origin with a F2 20209*T mutation and fetal loss or infertility. The functional analysis revealed that the F2 20209*T mutation stimulates 3' end processing and up-regulates prothrombin protein expression as assessed by a highly sensitive luminescence-based reporter system.
CONCLUSIONS: This is the first report of 20209*T in Caucasians, and functional analysis demonstrates that F2 20209*T falls into a general category of mutations of the F2 gene, which may possibly contribute to thrombophilia and complications of pregnancy by interfering with a tightly balanced architecture of non-canonical F2 3' end formation signals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16689762     DOI: 10.1111/j.1538-7836.2006.01885.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  9 in total

1.  Splicing factors stimulate polyadenylation via USEs at non-canonical 3' end formation signals.

Authors:  Sven Danckwardt; Isabelle Kaufmann; Marc Gentzel; Konrad U Foerstner; Anne-Susan Gantzert; Niels H Gehring; Gabriele Neu-Yilik; Peer Bork; Walter Keller; Matthias Wilm; Matthias W Hentze; Andreas E Kulozik
Journal:  EMBO J       Date:  2007-04-26       Impact factor: 11.598

Review 2.  3' end mRNA processing: molecular mechanisms and implications for health and disease.

Authors:  Sven Danckwardt; Matthias W Hentze; Andreas E Kulozik
Journal:  EMBO J       Date:  2008-02-06       Impact factor: 11.598

3.  Prothrombin C20209T mutation in deep vein thrombosis: a case report.

Authors:  Mariela Muñoz; Cristian Vilos; Mario Cantín
Journal:  Int J Clin Exp Med       Date:  2015-07-15

4.  Alterations in polyadenylation and its implications for endocrine disease.

Authors:  Anders Rehfeld; Mireya Plass; Anders Krogh; Lennart Friis-Hansen
Journal:  Front Endocrinol (Lausanne)       Date:  2013-05-08       Impact factor: 5.555

Review 5.  Pathologies at the nexus of blood coagulation and inflammation: thrombin in hemostasis, cancer, and beyond.

Authors:  Sven Danckwardt; Matthias W Hentze; Andreas E Kulozik
Journal:  J Mol Med (Berl)       Date:  2013-08-17       Impact factor: 4.599

Review 6.  Processing and transcriptome expansion at the mRNA 3' end in health and disease: finding the right end.

Authors:  Anton Ogorodnikov; Yulia Kargapolova; Sven Danckwardt
Journal:  Pflugers Arch       Date:  2016-05-25       Impact factor: 3.657

7.  C20209T prothrombin gene mutation associated deep venous thrombosis in a hemodialysis patient.

Authors:  Samer Bani-Hani; Omar Siddiqui; Anami Patel; Arif Showkat
Journal:  Clin Nephrol Case Stud       Date:  2014-01-15

Review 8.  Emerging Roles of RNA 3'-end Cleavage and Polyadenylation in Pathogenesis, Diagnosis and Therapy of Human Disorders.

Authors:  Jamie Nourse; Stefano Spada; Sven Danckwardt
Journal:  Biomolecules       Date:  2020-06-17

9.  A deep vein thrombosis caused by 20209C>T mutation in homozygosis of the prothrombin gene in a Caucasian patient.

Authors:  Silvia Izquierdo Alvarez; Eva Barrio Ollero; Francisco Miguel Llinares Sanjuan; Fabiola Lorente Martínez; María Teresa Calvo Martín
Journal:  Biochem Med (Zagreb)       Date:  2014-02-15       Impact factor: 2.313

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.